

Special Issue

Pathogenesis and Novel Diagnostic in Juvenile Idiopathic Arthritis

Message from the Guest Editor

The term 'juvenile idiopathic arthritis' (JIA) defines a heterogeneous collection of autoimmune or autoinflammatory forms of chronic arthritis with onset in childhood, with origins that are not yet entirely understood. There are no pathognomonic symptom or examination findings for JIA, and the diagnosis is made by exclusion and differentiation. JIA that is diagnosed too late or treated poorly treated may contribute to the disability of an afflicted child, due to disturbances in the structure and function of the osteoarticular system. Hence, prompt detection of structural disorders of articular cartilage would allow clinicians to initiate appropriate therapies, which is essential for the course of the arthropathy in question. Too late application of appropriate treatment, resulting from the lack of specific diagnostic biomarkers, may result in the perpetuation of pathological changes in the motor system in patients, or the development of systemic disorders, especially in those with high disease activity who require an aggressive therapy.

Guest Editor

Prof. Dr. Katarzyna Winsz-Szczotka

Laboratory Diagnostics, Department of Clinical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Sosnowiec, Poland

Deadline for manuscript submissions

closed (31 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/112933

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).